Summary statistics - qualitative results

EQA round: APLA2/26 - Antiphospholipid Antibodies

Deadline: 25.9.2026

Setup: all data

AV = assigned value
CVP = consensus of all participants
CVPG = consensus of the participants' groups
>>> ... expected result
> ... acceptable result
± ... result not assessed

N_{tot} = total number of the results
N_{rel} = relative number of the results

N_{eva} = number of the results assessed
N_{suc} = number of successful results
S_{rel} = relative success

Test / Sample / Group	AV	N_{tot}	N_{rel} [%]	Result	N_{eva}	N_{suc}	S_{rel} [%]
				Frequency of the results			**Success**
(465) **anti-β2-glycoprotein 1 screening**		10			0		
Sample A		10			10	10	100
All results	CVP >>>	10	100	Negative			
Sample B		10			0		
All results	±	2	20	Negative			
	±	2	20	Inconclusive result (borderline)			
	±	6	60	Positive			
(467) **anti-β2-glycoprotein 1 IgG**		60			60	59	98
Sample A		60			60	60	100
All results	CVP >>>	60	100	Negative			
Sample B		60			60	59	98
All results	CVP >>>	59	98	Negative			
		1	1,7	Inconclusive result (borderline)			
(468) **anti-β2-glycoprotein 1 IgM**		59			59	57	97
Sample A		59			59	59	100
All results	CVP >>>	59	100	Negative			
Sample B		59			59	57	97
All results		2	3,4	Negative			
	CVP >>>	57	97	Positive			
(461) **anti-cardiolipin screening**		12			12	12	100
Sample A		12			12	12	100
All results	CVP >>>	12	100	Negative			
Sample B		12			12	12	100
All results	CVP >>>	12	100	Positive			
(463) **anti-cardiolipin IgG**		63			63	63	100
Sample A		63			63	63	100
All results	CVP >>>	63	100	Negative			
Sample B		63			63	63	100
All results	CVP >>>	63	100	Negative			
(464) **anti-cardiolipin IgM**		63			55	52	95
Sample A		63			63	63	100
All results	CVP >>>	63	100	Negative			
Sample B		63			55	52	95
All results (without individual groups)		3	4,8	Negative			
	CVP >>>	52	83	Positive			
(166) Thermo Fisher	±	5	7,9	Inconclusive result (borderline)			
	±	3	4,8	Positive			